In This Article:
-
Revenue: $674.9 million, a decline of 5.4% year-on-year.
-
Adjusted EBITDA: $64.2 million, a decrease of 5.9% year-over-year.
-
Adjusted EBITDA Margin: 9.5%, compared to 9.6% in the prior year period.
-
Adjusted Net Income: $20.7 million, an increase of 3% year-over-year.
-
Book-to-Bill Ratio: 1.23 for the quarter.
-
Backlog: Approximately $7.6 billion, a growth of 6.2% over the past 12 months.
-
SG&A Expenses: Increased by 27.6% year-over-year.
-
Net Interest Expense: $22.4 million, a decrease of $12.2 million versus the prior year.
-
Effective Tax Rate: Benefit of 48.3% for the quarter.
-
Cash Flow from Operating Activities: $245.7 million for the nine months ended September 30, 2024.
-
Free Cash Flow: $217 million for the first nine months of 2024.
-
Days Sales Outstanding: 50 days as of September 30, 2024.
Release Date: November 08, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Fortrea Holdings Inc (NASDAQ:FTRE) achieved a book-to-bill ratio of 1.23 for the quarter, indicating strong demand and successful project acquisitions.
-
The company has made significant progress in exiting from its former parent, with over 90% of servers and application systems migrated to an independent environment.
-
Fortrea Holdings Inc (NASDAQ:FTRE) has been recognized externally, being named a finalist in Fierce Healthcare's excellence and data-driven DEI award and the CRO of the Year category in the annual script awards.
-
The company reported a solid pipeline of opportunities for the next two quarters, suggesting continued growth potential.
-
Fortrea Holdings Inc (NASDAQ:FTRE) has improved its Net Promoter Scores and customer satisfaction since becoming independent, reflecting enhanced customer relationships and service quality.
Negative Points
-
Revenues declined by 5.4% year-on-year, driven by lower service fee and pass-through revenues.
-
SG&A expenses increased by 27.6% year-over-year, primarily due to professional fees and costs related to exiting the transition services agreement.
-
Adjusted EBITDA decreased by 5.9% year-over-year, impacted by lower service fee revenues and higher SG&A costs.
-
The company faces ongoing challenges in fully exiting the transition services agreement, which is critical for future margin expansion.
-
Fortrea Holdings Inc (NASDAQ:FTRE) has not provided specific guidance for 2025, citing uncertainties related to the timing of TSA exits and the mix of new business awards.
Q & A Highlights
Q: Can you discuss the nature of studies in your clinical pharmacology (clinpharm) unit and whether GLP-1 categories are driving growth? A: Tom Pike, CEO: Our exposure is to large pharmaceutical firms and biotech globally, targeting organizations with strong spending. While we do some work on GLP-1, our exposure is broad across various sophisticated scientific therapies, including an interesting autoimmune compound in the UK.